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have been estimated in parallel with the
CEA values in a wide spectrum of clinical
stages in the evolution of colorectal cancer.
A combination of yGT and CEA gave an
improvement in the discrimination of hepatic
metastases but this combination still appears
to lead to error in some patients with residual
diseases apparently confined to the pelvis.
The rise in serum yGT is a more sensitive
indicator of early metastases than AP or
LAP, but once the level of yGT was above
100 i.u./ml (normal = 13-9 ± 7-7 i.u./ml) the
rate of rise of AP and LAP parallel the
increase of yGT. The rates of increase of
these enzymes in advanced hepatic metastases
have a fairly uniform course. On the other
hand, the levels ofCEA are extremely variable
and there is no simple correlation between the
apparent extent of the metastases and the
CEA level.
Following individual patients by repeated
measurements after the excision of the
primary tumour has shown that the com-
bination of CEA and yGT can indicate
metastatic cancer several months before
clinical examination. Furthermore, the treat-
ment of advanced colorectal cancer with
chemotherapy produces a fall in the yGT and
the CEA values. Unfortunately, this com-
bination of CEA and yGT is reliable as an
indicator of hepatic metastases in only a few
types of tumours. It failed to identify many
forms of cancer that gave positive evidence
of metastases on liver scintiscans. This
preliminary experience has suggested that it
may be possible to set up other combinations
oftumour antigens and chemical indicators of
organ site involvement to help in the sur-
veillance of common forms of cancer. This
may be particularly appropriate when suitable
forms of chemotherapy are available to
warrant early treatment.
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THERE ARE a number of reasons for
desiring a set of predictive tests in cancer
therapy. Since the number of patients who
respond to radiation, hormonal and cancer
therapy represents only a fraction of those
treated, it follows that many patients are
treated unnecessarily. Many therapies that
are used to treat non-resectable cancer have
toxic side-effects, so that if we could identify
patients who would surely fail, and omit
useless therapy, radiation and chemothera-
peutic toxicity could be diminished. If we
could predict that a conventional therapy
would fail, this would facilitate early intro-
duction of a new and possibly effective
treatment. Since it usually takes 3 or more
weeks to observe whether treatment is
effective, the replacement of clinical observa-
tion with a predictive test could very possibly
save 3 or more weeks of treatment. Since
the median survial of patients with, for
example, acute myelogenous leukaemia, is
only 3 weeks, half of such patients could be
offered a new and possibly effective therapy
before death. Recently, combination chemo-
therapy has become very popular and toxici-
ties not previously induced are now tolerated
because of possible increased benefits. Yet,
empirical choice of agents may result in
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effect. Furthermore, the mathematics of
combinations suggests that it may be
virtually impossible to distinguish whether
all or part of the drugs over 3 in number are
effective in a 4, 5 or 6 drug combinations.
The most suitable way of creating combina-
tions should be to select carefully just those
drugs which will be effective against a
particular patient's tumour. Thus, the
number of drugs would be restricted to those
predicted to be effective, and unnecessary
host toxicity would be reduced.
In vitro tests for drug sensitivity have
been clearly of great help in the treatment of
infectious diseases; however, these systems
cannot be readily transposed to the study of
therapy of malignancy. Firstly, human
tumours have never been grown routinely in
culture as have bacteria; the tumour cells
rarely proliferate, and thus leave only host
fibroblasts behind. Thus, the material in cell
culture is not representative of the three-
dimensional, vascularized nature of the
original tumour, neither do the cells in vitro
represent the frequency distribution of cell
types in the patient, nor do they undergo
proliferation and form targets for anti-
metabolite drugs that compare with the in
vivo situation. Secondly, many important
clinical factors such as excretion via the
urinary or gastrointestinal tracts, or the
possibility of hepatic activation or deamina-
tion of drugs cannot be mimicked in vitro.
Finally, the tumour cells appear to be more
highlyheterogeneous ormutablethanbacteria
in respect of their drug sensitivity and
resistance. All ofthese factors have made the
development of in vitro predictive test
systems extraordinarily difficult.
CLINICAL FACTORS
There are two biological approaches
establishing modern in vitro prediction
systems; one concerns the type of agent
involved and the other the tumour type. For
many years, a third modality, prediction by
clinical observation,was allthatwasavailable.
On this basis, some important concepts
developed concerning which disease patterns
carried less treatment responsiveness in a
number of diseases. Thus, in acute leukae-
mia, drug responsiveness seems lower in
older patients, in those with high white
counts and if the patient has had any prior
therapy. In childhood leukaemia, birth
order and zygosity seem also important. In
the lymphomata, increasing age is again a
predictor oftreatment resistance, as are some
histological types and possibly sex. Breast
cancers which occur in older women are more
responsive to hormone therapy than those in
young women. However, no such differences
are noted for response to non-hormonal
agents such as 5-fluorouracil, cyclophospha-
mide and the vinca alkaloids. The difference
in age does not appear to be a function ofhost
metabolism of hormones, but of the more
frequent occurrence in the older population
of tumours that have more cytoplasmic
steroid receptors, which may in turn be due
to the failing immunological surveillance
system of the older woman, thus permitting
increasing numbers of differentiated tumours
to " sneak through " and become clinically
apparent. It is thus important to realize that
the clinically recognized factors predictive of
good or poor response probably all have their
bases in identifiable cellular factors in the
host, the tumour, or both. Other clinical
factors which predict for differences in breast
cancer responsiveness include the " free
interval " or time between first treatment and
recurrence; the longer this is, the more
hormone responsive is the breast cancer.
Morphology of the tumour has also been
involved as a factor in the rate ofprogression:
In general, any tumour type which grows
slowly permits the physician to try more
agents and thus increase the chances of
hitting on a successful therapy. Thus,
medullary breast cancers and chronic leukae-
mias are considered more responsive to
treatment. Promyelocytic leukaemia, on the
other hand, is considered less responsive to
treatment because the survival is short.
However, in this instance, if the patient can
be kept alive, e.g., by anticoagulants, there is
no realevidencethatpromyelocyticleukaemia
cells are more drug resistant than other
myeloid cells. Thus, a false prediction of
drug responsiveness can be made on the basis
ofmorphology and clinical history unless one
separates true drug responsiveness of the
cancer cell from factors in the host or the
tumour cell which govern overall survival.
Host factors seem to be involved in deter-
mining that renal cell cancer responds well in
males and trophoblastic tumours most
readily in females. Tumour morphology also
seems to determine treatment responsiveness
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in thyroid, lung, endometrial and cervical
cancers. In the USA National Cancer Plan,
the study of predictive tests based upon
clinical observation has been called " thera-
peutic epidemiology ".
HOST FACTORS
In addition to clinical factors, consider-
able attention was given over the years to
factors by which different hosts might have
altered the drug target relationship in such
a way as to make a good drug ineffective in
some patients. In the case of the steroids,
extensive studies in the USA, and by the
groups led by Drs Bulbrook and Braunsberg
in England, failed to provide any clues as to
how either steroid metabolism by the host, or
blood levels and plasma transport, could be
shown responsible for the success or failure
of steroids. This may, with hindsight, not
be surprising, since it is probably unlikely
that the non-malignantly transformed host
tissues would exhibit indices of tumour cell
responsiveness. Also, any unique metabolic
product of the 1-2 kg tumour would well be
swamped by the contribution of 60 or 70 kg
of host normal tissue.
CELL AND DRUG KINETICS
More recently, attempts have been made
to discriminate between sensitive and non-
sensitive tumours on the basis of their cell
cycle kinetics. These attempts, too, have
been of little avail. The cell cycle kinetic
parameters of the highly resistant acute
myelogenous leukaemia of adults are indis-
tinguishable from those of acute lympho-
genous leukaemia which is very drug
sensitive. When patients with responsive
acute lymphoblastic leukaemia relapse after
becoming drug resistant, there are no dis-
cernable differences in cell cycle kinetic
characteristics. Cell cycle kinetic differences
might be expected to shed light on the differ-
ential responsiveness of slow growing and
fast growing tumours to cytotoxic and
antimetabolite drugs. However, none of the
available kinetic data shed light on the
strange fact that slow growing breast cancers
respond as well to antimitotic antimetabolites
such as methotrexate and 5-fluorouracil as to
" non-cycle active drugs " such as cyclophos-
phamide, vincristine and the sex steroids.
The same kinetically inexplicable paradox is
found in the drug responses of fast-growing
melanoma which responds not at all to
antimetabolites but responds, perversely, to
" cytotoxics " such as the mustards and
dimethylimidazolecarboxamide.
One must add, however, that once a drug
is shown to be active against a tumour or
class of cancer, knowledge of the tumour's
mitotic cycle characteristics may be of help
in designing improved regimens for clinical
use.
If there are no predictive differences in
cycle kinetics which differentiate sensitive
from resistant tumour cells, could there be
differences between the drug blood levels,
plasma binding, and excretory rates in
sensitive and resistant patients? The lack of
success with the steroids would not have
presaged a good outcome for such investiga-
tions. However, in contrast to the steroids,
other chemotherapeutic agents are foreign to
the body and are given in small quantities so
that pharmacokinetic differences might be of
greater imprortance. The data to date have
not indicated any exploitable differences
between the pharmacokinetics of any drug
in patients who have drug sensitive or
resistant tumours. This is not to suggest
that there are no pharmacokinetic differences
between drugs or patients. For example,
Adriamycin hasamuchlonger plasma half-life
than 5-fluorouracil, and this half-life is even
more prolonged in patients with liver disease.
Nevertheless, they are both effective in
patients with breast cancer and there is no
evidence that the reason that Adriamycin is
better for sarcomata than 5-fluorouracil is the
difference in the drug half-life in sarcoma
patients.
PHARMACOMETRICS
We come then to the measurement of
differential drug metabolism by the tumour
and the normal as a basis for general drug
effectiveness and for the differences between
sensitive and resistant tumours. This area of
study might be called " oncoprognostic
pharmacometrics ". In order best to examine
the cellular factors that are involved in
response to cancer therapy, we must realize
that anti-cancer therapies are of several quite
distinct types in terms of their action upon
target and host cells. Not all of the drugs
193B.A.C.R. 15TH ANNUAL GENERAL MEETING
used are selectively toxic to tumours; many
are based upon the presumption of close
similarity between the tumour and its normal
tissue of origin and have quite different
intracellular actions from simple cytotoxity
or cell killing. This important fact must be
kept in mind lest an undesirable over-
emphasis be placed upon the concept of
" killing " to the exclusion ofother important
determinants of drug effectivenss.
Oncoprival chemotherapy is that in which
the tumour is deprived of a normal substance
which is needed for its proliferation. The
normal substances would generally be the
same as those which are responsible for the
continued proliferation of normal tissues in
the adult organism. The small amounts of
ovarian oestrogen which promote the growth
of breast cancers, in perhaps 25% of young
women, are examples ofthis class. Oncoprival
treatment may be surgical e.g., oophorectomy,
orradiation e.g., castration, orfollow cessation
of oestrogen biosynthesis e.g. by amino-
glutethimide administration. In these in-
stances the normal tissue is also deprived of
the growth factor but the loss of normal
breast cells is not important or even notable
in the cancer patient. A comparable onco-
prival therapy is available forthetreatment of
prostate cancer by orchidectomy and ad-
renalectomy. Other examples of oncoprival
therapy include removal of the exogenous
asparagine which is needed for the mainten-
ance of normal lymphocytes. After removal
of this amino acid, lymphocytes cannot
proliferate and since lymphoproliferative
cancer cells closely resemble normal lympho-
cytes in their asparagine dependency, they
are subject to oncoprival therapy with
I-asparaginase. Apparentlylymphocytes and
lymphomata also share a selective depen-
dency upon vitamin B6 and its derivatives,
since a diet deficient in pyridoxine and
supplemented by desoxypyridoxine causes
lymphopenia and regression of a number of
lymphomata. The primary determinants of
steroid responsiveness in target cells appear
to be the presence in the cytoplasm ofspecific
protein " steroid receptors " which are in-
volved in the binding ofthe steroids and their
transport to the nucleus, following which the
sequences of RNA transcription and new
protein synthesis result in the growth or
differentiation of the target cell. Since small
amounts of the steroids cause proliferation of
the target tissues, it now appears possible to
predict which breast cancers will respond to
oophorectomy since such tumours should, and
apparently do, contain significant amounts of
oestrogen receptors.
Ontoductive therapy, on the other hand,
does not attempt to prevent tumour cell
proliferation but attempts instead to cause
the target cell to differentiate further
toward normality. Again, there is no
attempt to kill cells selectively. Rather, we
assume that first, the tumour cell is rather
more like the normal than different from it
and second, that massive doses of a normal
differentiation-promoting substance might
cause the tumour to mature, differentiate and
stop proliferating. The use of massive
pharmacological doses of the sex steroids in
breast cancer, and the topical application of
vitamin A in papillomata are examples of
treatment which " conducts " the tumour
further along the path of its own potential
ontogeny. The nature of the substances
involved should be best studied in normal
tissues, as would be true for the determinants
ofthis special anti-tumour effect. In the case
of the steroids, we find suggestive evidence
that the same cytoplasmic receptors are
involved, so that the same in vitro receptor
assay predicts for response to oophorectomy
in the young patient and for exogenous
steroids in the post-menopausal patient. To
date, no studies of possible cytoplasmic or
nuclear binding of vitamin A have come to
my attention, but the elegant studies of
Dame Honor Fell on vitamin A induced
overdifferentiation of chicken skin may
provide a model for detection of the loci of
vitamin A binding and action in those
tumours which will be found to respond to it.
At present, there is good evidence that
differentiation ofnormal tissues promoted by
androgens andprogestinsrequires cytoplasmic
receptors. In our laboratories and in others,
attempts are currently being made to relate
steroid sensitivity in prostate, and endo-
metrial tumours to the presence of specific
receptors.
Ontotoxic chemotherapy is a name we have
given to describe the actions of steroids
which inhibit both proliferation and differ-
entiation of the target tissue. These may be
best exemplified by the " contralateral "
steroid effect, i.e., the inhibiting effect of
androgens upon normal breast epithelium and
upon breast tumours which resemble differ-
entiated normal breast tissue to the extent
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that they also atrophy when exposed to high
concentrations ofthe opposite sex steroid. A
similar inhibition of normal and malignant
prostate epithelium has been noted with high
dose oestrogen therapy. The molecular basis
for the differential effect of the " ipsilateral "
and " contralateral " sex steroids is not
known; possibly competition for nuclear
receptor sites or different sites for gene
activation may be involved. However, it has
long been observed that a good breast cancer
response to oestrogen is frequently followed
by an equallygood response later to androgen,
suggesting that either one receptor is in-
volved, or that both receptors tend to be
present in the same cell. Terenius has
described a remarkably high degree of
correlation between the presence of oestrogen
and progestin receptors in human tumours.
Hence, quite interestingly, the presence of
steroid receptors in a tissue may predict for
response to oncoprival, ontoductive and
ontotoxic therapies.
Histotoxic therapy is directed toward the
normal tissue from which a tumour has
arisen. It is based upon the hope that the
tumour closely resembles the normal tissue
so that killing the normal tissue will inci-
dentally kill the tumour. Hence, the pre-
dictive determinants of this nonselective
toxicity should be best found by examination
of the normal tissues. Among the outstand-
ing examples of this type of therapy are the
lympholytic actions of mustards, 1-aspara-
ginase and corticoids, the adrenolytic action
of Op'DDD, the islet cell toxicity of strepto-
zotocin and the abortifacient action of
methotrexate. In this wide variety of drugs
and tumours, the determinant of anti-
tumour response is how closely the tumour
resembles the normal tissue. In the case of
the corticoids, there is good evidence that the
lympholytic action follows the binding of the
corticoid in the cytoplasm by a protein
mechanism resembling that for the sex
steroids and progestin. However, the subse-
quent events do not seem to involve pro-
liferation or differentiation into a stable
end-cell; rather they result in death of the
lymphocyte. This suggests that the ultimate
differentiated fate of the lymphocyte is to
lyse and deliver its products to the rest ofthe
body. The possibility that comparable
binding proteins might be involved in the
action of Op'DDD and streptozotocin needs
careful investigation.
Inthe case of1-asparaginase, a remarkable
logical error was committed by some who
failed to recognize the primary lympholytic
effects ofthe drug and erroneously attributed
its action to a " unique requirement " by
tumour for asparagine. We now realize that
precisely the opposite is the case, that
asparaginase works onlyon lymphatic tumour
cells which are very like normal lymphocytes
in their asparagine dependency. A number
of predictive tests have been devised for this
agent:(1) The amount of asparaginase syn-
thetase in a tissue can be used to determine
freedom from asparagine dependency and
hence from asparaginase effect; (2) Cells
made resistant to 1-asparaginase in vitro also
change their membranes to contain fewer
asparagine residues, since these residues in
drug sensitive cells appear to be hydrolysed,
with rupture ofthe cell (Kessel and Bosman,
1972). Since asparagine forms one of the
major links between the protein backbone
and sugar residues in the cell membrane, the
reduction of asparagine residues in 1-aspara-
ginase resistance is also accompanied by a
decrease in total anthrone positive material
in the membranes of such resistant cells in
culture. This forms the basis of a predictive
test for asparagine sensitivity and an explana-
tion for the resistance ofmyelogenous cells to
asparaginase which is currently under study
in our laboratories.
Mitotoxic chemotherapy is commonly, but
erroneously, thought of as the only type of
chemotherapy. Such therapy, directed
against the proliferative qualities oftumours,
carries an unavoidable burden of toxicity to
the rapidly growing tissues of the host,
particularly the gastrointestinal epithelia,
bone marrow and skin with its appendages.
The antimetabolites comprise a major sub-
class of such agents, with methotrexate being
the type compound for folate antagonists
designed to inhibit dihydrofolate reductase
(dHFR) activity and in so doing prevent the
biosynthesis of de novo thymidine. Although
methotrexate induced resistance is accom-
panied by increases in intracellular content
of dHFR in some animal tumours, Roberts
and Hall (1969) found that the "innate"
sensitivity of mouse tumours which had not
been exposed to the drug was not related to
dHFR concentration. Kessel, Hall and
Roberts (1968) found that the actual in vivo
determinant of innate sensitivity was trans-
port of the drug into mouse and human
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leukaemic cells. This sequence of experi-
ments pointed out that: (1) there were great
differences between " innate " and drug-
induced or " acquired " drug resistance, to
say nothing of " collateral " changes in
sensitivity to one drug acquired pari-passu
during treatment with a quite different drug;
(2) " innate " drug sensitivity may com-
monly be explained by a single predictive
determinant, but in cases of drug induced
resistance, more than one mechanism is
commonly involved, as for example, a drop
in transmembrane transport of methotrexate,
plus an elevation of dHFR, plus a switch
from the utilization of deoxyuridylate to
thymidylate for DNA synthesis.
Six-mercaptopurine (6 MP), like mostanti-
metabolite bases, diffuses freely into target
cells but requires phosphorylation to a
nucleotide. A predictive test for sensitivity
to 6 MP can thus be designed for rodent and
for human leukaemic cells, based upon the
activity of a guanine-hypoxanthine phospho-
ribosyl-transferase. This assay does not
predict well unless whole cells are used, and
innate sensitivity is being sought (Kessel and
Hall, 1969). In certain leukaemias which
were treated with 6 MP, the development of
acquired resistance could be shown also to be
correlated with the appearance of a phospha-
tase which hydrolysed the 6 MP nucleotide,
so that separate tests may be needed for
clinical use depending upon the prior exposure
of the patient to the drug (Wollpert et al.,
1971). It would be of great interest to check
whether the virtually complete resistance
of human solid tumours to 6 MP was due
to a relative absence ofguanine-hypoxanthine
phosphoribosyltransferase from such tumours.
In the case of5-fluorouracil, conversion to
a nucleotide is necessary for the activation of
the drug, and anti-tumour activity is propor-
tional to the amount of FUMP formed. In
human leucocytes the lack of both nucleoside
phosphorylase, to convert FU to FUR, and of
a pyrimidine phosphoribosyltransferase, to
convert FU to FUMP, makes human leukae-
mic cells resistant to FU (Hall et al., 1968).
It has been estimated that the application of
these predictive tests at a cost of possibly
$10,000 could have prevented clinical trials
of FUand FUdR in human leukaemia costing
20 times as much, to say nothing ofthe loss of
critical treatment time by the patients
involved. In the case of animal solid
tumours, the determining enzyme appears to
be the pyrimidine phosphoribosyltransferase,
and preliminary studies to date suggest that
the same enzyme is predictive for response of
colon and breast cancers to 5-fluorouracil
(Keyes and Hall, 1969).
Phosphorylation is also the determinant
of activity of nucleosides such as cytarabine,
both in murine and human leukaemic cells
(Kessel, Hall and Rosenthal, 1969). For a
while, deamination of cytarabine by target
cells was thought to be a possible determinant
of response, but it does not appear that this
enzyme plays an important role in the predic-
tion of response (Stewart and Burke, 1971;
Hall and Levine, 1967). The relative
ineffectiveness of cytarabine in the treatment
of human solid tumours suggests that there is
a relative lack ofdeoxycytidine kinase in such
tumours.
The alkylating agents and radiation both
produce nicks and defects in the DNA
molecule and there is evidence, from the
shape of the shoulder at low doses on the
survival curves for both agents, that DNA
repair may be involved. This is also sug-
gested by animal work on myeloma with
repair inhibitors and by the increased
radiation sensitivity of cells such as those in
xeroderma pigmentosum, in which repair is
defective and delayed (Setlow et al., 1969).
We are at present developing an assay for
potential radiation and alkylating agent
sensitivity based upon the DNA repair
capacity ofthe cells to be treated (Leiberman
et al., 1971).
Many of the larger heterocyclic molecules
seem to have difficulty in getting transported
across the cell membranes of animal tumour
cells which are resistant to the drugs in
question (Kessel and Bosmann, 1970). In-
duction of resistance to actinomycin D, and
to vincristine, daunorubicin and some tere-
phthalanalides, can be shown to be mediated
by a similarmechanism in which there is more
transfer of glycoprotein residues into the
tumour cell membrane and an accumulation
of anthrone-positive material, suggesting a
thickened cell membrane (Bosmann and
Kessel, 1971). It is interesting to speculate
whether these characteristics are more like
those usually found in the glycocalyx of an
epithelial cell, even a tumour cell, as con-
trasted with the thinner cell membranes of
mesenchymal cells; possibly such differences
could permit easier ingress of such molecules
to themesenchymal tumour cells ofsarcomata
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and lymphomata and thus predict the rela-
tively greater effectiveness ofsuch compounds
for mesenchymal as opposed to epithelial
tumours. We were able to predict campto-
thecin resistance by rendering a murine
lymphoma resistant to actinomycin D and
daunorubicin. These concepts contain the
seeds of a prediction system for this whole
class of compounds which we are presently
studying. If such membrane changes result
in similar lack of uptake by human tumours,
it might be simpler to give a pulse dose ofthe
compound in question in tracer labelled form
and measure the differential uptake observed
at subsequent biopsy.
When the uptake of methotrexate or of
actinomycin and similar compounds is at an
intermediate level, or the amount of anti-
metabolite nucleotide accumulated intracel-
lularly is at an equivocal level, it may be
possible to increase the efficiency of the
prediction system by giving a test dose of the
drug in question and following the subsequent
effects on macromolecular biosynthesis (Hall
et al., 1973). This can only be done in
tumours which permit repeated biopsies,
such as in a patient with multiple skin
masses, or in leukaemia, or in the case of
malignant effusions. The uptake of 32p or an
1311 or 125J labelled base ornucleoside can also
be measured by external radioisotopic moni-
tors, but the data tend to be less precise
because of the problems of collimation and
quantitation (Nathanson, 1971).
In the other instances, single ineffective
drugs to not cause a drop in the 24-hour
utilization of UdR (deoxyuridine) or TdR
(thymidine) for DNA synthesis, and such
drugs can therefore be omitted from the
treatment programme. After one effective
drug is found, the DNA synthesis may not
return to near the initial rate for some time,
and thus impair the testing of subsequent
drugs.
APPLICATION
The application of such predictive tests
has resulted in improved selection of drug
regimens for the treatment of acute myelo-
genous leukaemia. The optimal combination
oftests included measurements ofuptake and
phosphorylation of methotrexate, 6 MP and
cytarabine, followed by observations on serial
changes in DNA synthesis following adminis-
tration of single full-dose pulses when uptake
levels were intermediate and of cyclophos-
phamide, vincristine and daunorubicin. With
this method, there were no false negative or
positive results. The number of responses
was not altered but the failures were identified
and could have had their treatment stopped
in favour of newer and more promising
agents.
In the case of breast cancer, oestrogen
receptors have been shown to be predictive of
response to oophorectomy, adrenalectomy
and hypophysectomy (oncoprival therapy).
The data on the ontoductive effects of
massive pharmacological doses of the sex
steroids on breast cancer are not numerous
yet, but all those available from a number of
sources are consistent in support of a predic-
tive role in ontoductive therapy for tumour
steroid receptors.
The data are accumulating on colon and
breast cancer with regard to treatment with
5-fluorouracil, and at the present time suggest
that low levels of pyrimidine phosphoribosyl-
transferase do not permit response to FU,
whereas high levels in the tumours predispose
to 5 FU induction of response.
Further studies are under way in respect
of DNA repair in human lymphoma response
to mustards, and of the multiple factors
involved in predicting response to lymphoma
and breast treatment combinations.
SUMMARY
In vitro measurements of drug-tumour
interactions have not been ofhelp in selecting
improved therapeutic regimens for individual
patients. Studies of human pharmaco-
kinetics on cell kinetics have also not been of
help. In vivo and in vitro measurements of
drug handling by and drug effects upon
tumour tissue, however, have been of con-
siderable help.
At present a definite test for methotrexate,
6-mercaptopurine, 6-thioguanine and cytara-
bine sensitivity in leukaemias is the uptake
and retention of the active form of the drug.
The presence ofan oestrogen receptor appears
to predict well for response to the oncoprival,
ontoductive and ontotoxic effects of steroids.
A number of other tests appear to predict
well for response to therapy. These include
breast and colon tumour levels of the phos-
phoribosyl-transerase for 5-fluorouracil, and
the reduction and binding of testosterone by
breast tissue. Differential tumour uptake of
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actinomycin D, adriamycin and mustards are
also in this category. Receptors for corticoids
and progestins appear ready to exploit in the
treatment oflymphoproliferative cancers and
endometrial cancer.
Tests which show promise of applications
to the human situation include the measure-
ments of membrane glycosidases and glyco-
proteins transferases for heterocyclic comn-
pounds, and the measurement of specific
repair enzymes for sensitivity to the alkylat-
ing agents and to x-irradiation.
The original work referred to is the pro-
duct of collaborative efforts with Drs David
Kessel, H. Bruce Busmann, Aly Nahas,
De Wayne Roberts and Bruce Hacker.
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